Family Medicine Doctors in Audubon, IA Accepting Medicare
4 Family Medicine doctors found. Showing 1 - 4
 Terry L Sprague, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 222 Broadway, Audubon Medical Clinic, Audubon, IA 50025 Phone: 712-563-4206 Fax: 712-563-2001 |
Charles Ryan Burkett, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 515 Pacific Ave Ste 2, Audubon, IA 50025 Phone: 712-563-4611 Fax: 412-563-2498 |
James Michael Cunningham, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 515 Pacific Ave Ste 2, Audubon, IA 50025 Phone: 712-563-4611 Fax: 712-563-2498 |
 Dr. Stephanie Vampola-runyan, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 515 Pacific Ave, Audubon, IA 50025 Phone: 712-563-4611 Fax: 563-742-4355 |
News Archive
New device uses single drop of blood to diagnose mild traumatic brain injury
Every year in Europe, three million people are admitted into hospitals for suspected mild traumatic brain injury cases. Yet 90% of these patients will be able to return home safely, as no trauma has been detected.
'Brain Glue' could one day serve as treatment for TBIs
Researchers at the University of Georgia's Regenerative Bioscience Center have developed Brain Glue, a substance that could one day serve as a treatment for traumatic brain injuries, or TBIs.
Cytori Therapeutics' PureGraft System receives FDA marketing clearance
The FDA has granted Cytori Therapeutics 510(k) marketing clearance for its PureGraft™ System. Cytori will now launch the first and only device in the United States cleared for aesthetic body contouring using autologous fat. PureGraft™ allows a patient's own fat tissue to rapidly be prepared in approximately 15 minutes for re-injection back into the same patient for aesthetic contouring.
Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout
Ardea Biosciences, Inc. announced that additional positive clinical and preclinical results from its development program of lesinurad, the Company's lead product candidate for the treatment of hyperuricemia and gout, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism in London, UK.
› Verified 4 days ago